Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13040091 | 0.81 | TYR (0.38) | KEAP1NFE2L2TLR8 | |
| SCHEMBL336213 | 0.80 | KEAP1 (0.47) | KEAP1NFE2L2 | |
| SCHEMBL30453502 | 0.80 | KEAP1 (0.47) | KEAP1NFE2L2 | |
| SCHEMBL29010115 | 0.80 | KEAP1 (0.49) | KEAP1NFE2L2 | |
| SCHEMBL13040092 | 0.77 | KEAP1 (0.40) | KEAP1NFE2L2 | |
| SCHEMBL29009801 | 0.75 | KEAP1 (0.51) | KEAP1NFE2L2 | |
| SCHEMBL6222736 | 0.74 | KMT2A (0.47) | KEAP1NFE2L2 | |
| SCHEMBL15760104 | 0.73 | KEAP1 (0.41) | KEAP1NFE2L2 | |
| SCHEMBL5044728 | 0.72 | KEAP1 (0.42) | KEAP1NFE2L2 | |
| SCHEMBL8235127 | 0.72 | KEAP1 (0.47) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | KEAP1 1099/4885NFE2L2 326/4885CA2 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.